Evidence designed for real decisions – built to support coverage and adoption.
TTi Health Research & Economics is a specialized RWE & HEOR CRO supporting MedTech and Precision Medicine companies as they move from clinical trials to reimbursement, coverage, and adoption.
We design and execute payer-focused evidence strategies that integrate clinical trial data, real-world outcomes, and economic value—ensuring coverage, pricing, and access decisions are supported by evidence that matters.
Our work is grounded in real-world feasibility, aligned with payer and health system expectations, and built to support decision-making across the product lifecycle.
Real-World Evidence (RWE) Studies
We design and execute real-world evidence studies that extend and reinforce clinical trial findings to support payer, health system, and coverage decisions.
Our RWE work focuses on demonstrating how technologies perform in real-world settings, patient populations, and care pathways, helping decision-makers assess value beyond controlled trial environments.
Our RWE work includes:
-
Observational and pragmatic study designs
-
Prospective and retrospective real-world studies
-
Evidence generation aligned with payer and HTA expectations
-
Study designs that complement and contextualize existing clinical data
Outcome: Evidence that supports reimbursement discussions, coverage evaluations, and clear value demonstration.
Clinical Trials & Evidence Generation
We design and support clinical studies that generate evidence to support coverage, reimbursement, and adoption—not just safety and performance.
Our work focuses on ensuring clinical trials are payer-informed and decision-relevant, often by incorporating the right endpoints, comparators, and outcomes data into ongoing or planned studies.
Our work includes:
-
Payer-informed trial design and endpoint selection
-
Add-on utilization, economic, and outcomes data within trials
-
Pragmatic and hybrid study designs aligned with real-world use
-
Clear linkage from clinical trial results to follow-on evidence
Outcome: Clinical evidence that supports reimbursement decisions, coverage evaluations, and early market uptake.
Health Economics & Outcomes Research
We deliver health economic analyses that translate clinical trial and real-world outcomes into clear, decision-relevant economic value for payers, health systems, and other decision-makers.
Our HEOR work helps organizations quantify cost, utilization, and value trade-offs in ways that align with payer evidence requirements and real-world reimbursement decisions.
Our HEOR capabilities include:
-
Budget impact models
-
Cost-effectiveness and cost-utility analyses
-
Economic modeling aligned with payer decision frameworks
-
Value narratives that support pricing and contracting strategies
Outcome: Clear, defensible economic evidence that supports reimbursement and market access decisions.
Trusted by innovators, payers, and health system partners
From Clearance to Coverage and Adoption
Your product is cleared or your clinical study is underway—but access depends on demonstrating value beyond safety and performance.
We help early commercial-stage companies generate payer-relevant clinical, real-world, and economic evidence that supports:
-
Coding applications and refinements
-
Initial coverage determinations
-
Health system and IDN uptake
-
Clinician confidence and early adoption
Where possible, we enhance ongoing clinical trials with the right endpoints and outcomes data—so you get the evidence you need without starting over.
Outcome: Evidence that accelerates reimbursement, coverage, and early market traction.
Evidence That Keeps Pace With Commercial Momentum
As adoption increases, evidence requirements evolve—and expectations from payers and health systems become more rigorous.
We support growing MedTech companies that need to expand and defend coverage, reinforce value narratives, and respond to payer and health system questions without slowing commercial execution.
Our work focuses on generating decision-ready clinical, real-world, and economic evidence that supports:
-
Coverage expansion and consistency across payers
-
Pricing and value defense in competitive markets
-
New use cases, indications, or patient populations
-
Ongoing payer, IDN, and health system reviews
Outcome: Evidence that protects access, reinforces value, and enables confident, sustainable scale.
Sustaining Access and Differentiation Over Time
Even for well-established products, evidence remains essential to defending value in increasingly competitive markets.
We support companies with established products that need to reinforce coverage, respond to evolving payer expectations, and demonstrate ongoing value to health systems and decision-makers.
Our work focuses on generating clinical and economic evidence that supports:
-
Value analysis and technology assessment
-
Coverage applications, updates, and renewals
-
Guideline discussions and clinical positioning
-
Value dossiers and payer communications
Outcome: Evidence that strengthens competitive positioning, and supports continued market leadership.